G. Steven Burrill

An introduction to Burrill Venture Capital

Flash required to view this video. Download the latest version here

 G. Steven Burrill 

News

Biotech takes a beating in market meltdown October 01, 2008 | Press Release

Biotech outperforms market in May June 02, 2008 | Press Release

Biotech Treads Water in April May 01, 2008 | Press Release

  See all News
Sign up to receive email notifications about our upcoming events and news.


Submit a Business Plan

Do great things with us.Click here 
Venture Capital

 


Nora Therapeutics is an early stage specialty biopharmaceuticals company focusing on commercializing therapeutics to address issues in reproductive health. Based on medical research in immunology and supported by a strong intellectual property position, Nora’s lead therapeutic candidates are FDA-approved products repurposed to improve the likelihood for term pregnancy in women who suffer from repeated assisted reproductive failure (i.e., in vitro fertilization or IVF) and recurrent miscarriage.